AGMH vs IMTE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AGMH exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, raising concerns about default risk. The company trades at a deeply undervalued price of $1.16, significantly below its Graham Number ($115.24) and intrinsic value ($228.13), suggesting potential undervaluation. However, this is offset by extreme price volatility, a 5-year return of -99.8%, and a lack of analyst coverage. Despite strong profitability metrics like a 31.41% profit margin and 95.31% ROE, the company's negative operating margin (-1.60%) and absence of cash flow data undermine sustainability. The stock's massive revenue growth (430.70% YoY) is likely unsustainable and may be driven by one-time or non-recurring factors.
IMTE exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic operating margin of -6184.81%. The company faces a liquidity crisis with a current ratio of 0.72, indicating an inability to cover short-term obligations. While the Price-to-Book ratio is low (0.17), the Price-to-Sales ratio of 33.21 is unjustifiably high for a company with no profitability. Long-term price performance is devastating, with a 98.5% decline over five years, suggesting a fundamental collapse of value.
Compare Another Pair
Related Comparisons
AGMH vs IMTE: Head-to-Head Comparison
This page compares AGM Group Holdings Inc. (AGMH) and Integrated Media Technology Limited (IMTE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.